FindTrial
Sign In

Diagnostic performance of SAFE score

Diagnostic performance of SAFE score

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008705
Enrollment
30000
Registered
2023-08-11
Start date
2022-11-08
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Hanyang University Seoul Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Among patients who performed liver fibrosis scan at the Department of Gastroenterology between 2018 and 2021, the SAFE score can be calculated

Exclusion criteria

Exclusion criteria: 1) Fibroscan 2) Insufficient or missing tests to determine SAFE

Design outcomes

Primary

MeasureTime frame
SAFE prediction model, a new evaluation index, describes sensitivity, specificity, and AUROC to predict intrahepatic fibrosis when hepatic fibrosis scan is used as the gold standard—

Secondary

MeasureTime frame
The sensitivity, specificity, and AUROC of the SAFE score were analyzed in subgroups divided into the presence of fatty liver, diabetes, and metabolic syndrome.—

Countries

Korea, Republic of

Contacts

Public ContactDae Won Jun

Hanyang University

gongori1004@gmail.com+82-2-2290-8334

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026